OMEROS CORP Gain (Loss) on Extinguishment of Debt
OMEROS CORP (OMER) reported Gain (Loss) on Extinguishment of Debt of $0 for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2025-11-13
- OMEROS CORP gain (loss) on extinguishment of debt for the quarter ending 2025-09-30 was $0.00.
- OMEROS CORP gain (loss) on extinguishment of debt for the quarter ending 2025-06-30 was -$2.97M.
- OMEROS CORP gain (loss) on extinguishment of debt for the quarter ending 2024-12-31 was $0.00.
- OMEROS CORP gain (loss) on extinguishment of debt for the quarter ending 2024-09-30 was $0.00.
- OMEROS CORP gain (loss) on extinguishment of debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- OMEROS CORP gain (loss) on extinguishment of debt for fiscal 2023 was $4.11M.
- OMEROS CORP gain (loss) on extinguishment of debt for fiscal 2022 was $0.00.
- OMEROS CORP gain (loss) on extinguishment of debt for fiscal 2021 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month | Gain (Loss) on Extinguishment of Debt 204 month | Gain (Loss) on Extinguishment of Debt 207 month |
|---|---|---|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 | -$2.97M derived: sum of 2 quarters · filed 2025-11-13 | -$2.97M 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | -$2.97M 10-Q · filed 2025-08-14 | -$2.97M 10-Q · filed 2025-08-14 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 derived: sum of 3 quarters · filed 2025-11-13 | $0.00 10-K · filed 2025-03-31 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | ||||
| 2023-12-31 | $4.11M 10-K · filed 2025-03-31 | |||||
| 2022-12-31 | $0.00 10-K · filed 2025-03-31 | |||||
| 2021-12-31 | $0.00 10-K · filed 2024-04-01 | |||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | -$13.37M derived: sum of 2 quarters · filed 2023-03-13 | -$13.37M 10-K · filed 2023-03-13 | |||
| 2020-09-30 | -$13.37M 10-Q · filed 2021-11-09 | -$13.37M 10-Q · filed 2021-11-09 | ||||
| 2018-12-31 | -$12.99M 10-K · filed 2021-03-01 | |||||
| 2017-12-31 | $0.00 10-K · filed 2019-03-01 | |||||
| 2016-12-31 | -$5.59M 10-K · filed 2019-03-01 | |||||
| 2015-12-31 | -$1.31M 10-K · filed 2018-03-01 | |||||
| 2014-12-31 | $0.00 10-K · filed 2017-03-16 | |||||
| 2013-12-31 | $0.00 10-K · filed 2016-03-15 | |||||
| 2011-09-30 | $0.00 derived: 10-Q 207 month − 10-Q 204 month · filed 2011-11-08 | -$296.00K 10-Q · filed 2011-11-08 | ||||
| 2011-06-30 | -$296.00K 10-Q · filed 2011-08-09 | |||||
| 2010-12-31 | -$296.00K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |